US Patent

US12343382 — Methods of using a GIP/GLP1 co-agonist for therapy

Method of Use · Assigned to Eli Lilly and Co · Expires 2039-07-22 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using tirzepatide to increase glycemic control, improve weight management, treat certain conditions, and prevent or induce remission of diabetes.

USPTO Abstract

The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and/or treating dyslipidemia.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4400 — Mounjaro
U-4410 — Mounjaro
U-4227 — Mounjaro
U-4228 — Mounjaro
U-4228 — Mounjaro
U-4400 — Mounjaro
U-4232 — Mounjaro
U-4232 — Mounjaro
U-4401 — Mounjaro
U-4229 — Mounjaro
U-4401 — Mounjaro
U-4400 — Mounjaro
U-4400 — Mounjaro
U-4228 — Mounjaro
U-4228 — Mounjaro
U-4229 — Mounjaro
U-4229 — Mounjaro
U-4409 — Mounjaro
U-4409 — Mounjaro
U-4227 — Mounjaro
U-4228 — Mounjaro
U-4228 — Mounjaro
U-4228 — Mounjaro
U-4228 — Mounjaro
U-4229 — Mounjaro
U-4229 — Mounjaro
U-4229 — Mounjaro
U-4228 — Mounjaro
U-4228 — Mounjaro
U-4229 — Mounjaro
U-4229 — Mounjaro
U-4400 — Mounjaro
U-4400 — Mounjaro
U-4400 — Mounjaro
U-4400 — Mounjaro
U-4400 — Mounjaro
U-4409 — Mounjaro
U-4409 — Mounjaro
U-4228 — Mounjaro
U-4228 — Mounjaro
U-4228 — Mounjaro
U-4228 — Mounjaro
U-4228 — Mounjaro
U-4228 — Mounjaro
U-4228 — Mounjaro
U-4229 — Mounjaro
U-4230 — Mounjaro
U-4230 — Mounjaro

Patent Metadata

Patent number
US12343382
Jurisdiction
US
Classification
Method of Use
Expires
2039-07-22
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.